Abalos Therapeutics scores $50m Series A extension

Abalos Therapeutics, an immuno-biotherapeutics company that targets cancer cells, has secured a $50 million extension to its Series A round.

14 October 2021•3 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles